Pear Therapeutics: Why FDA Approval Isn’t Enough for AI Health

The narrative surrounding AI in healthcare often glows with the promise of disruption, efficiency, and improved patient outcomes. Yet, the spectacular implosion of Pear Therapeutics serves as a stark, cautionary tale for investors and health plans alike: FDA clearance, while a critical hurdle, is not a guarantee of commercial viability. The journey from a peak valuation of $1.6 billion to a mere $6.05 million asset sale underscores a fundamental truth in the AI health sector: regulatory approval without a clear, sustainable reimbursement pathway is, effectively, a death sentence.

The Precipitous Decline of a Digital Therapeutics Pioneer

Pear Therapeutics, once heralded as a trailblazer in digital therapeutics (DTx), achieved what many AI health companies aspire to: multiple FDA clearances. Their lead product, reSET, for substance use disorder, and reSET-O, for opioid use disorder, received FDA De Novo classification. This pathway is reserved for novel, low-to-moderate-risk devices with no predicate, signifying a truly innovative approach to care. Later, their Somryst for chronic insomnia also secured FDA clearance. These regulatory achievements positioned Pear as a leader, seemingly validating the clinical efficacy and safety of their software as a medical device (SaMD).

However, the company’s trajectory from a $1.6 billion peak valuation to its eventual asset sale for $6.05 million reveals a chasm between regulatory success and market adoption. Despite these clearances, Pear struggled profoundly with securing consistent and scalable reimbursement. Unlike traditional pharmaceuticals or medical devices, digital therapeutics faced an uphill battle convincing payers, health plans and CMS, to cover these new modalities. The challenge wasn’t just about demonstrating clinical outcomes, which Pear had done through rigorous trials, but about integrating these solutions into existing reimbursement structures and workflows. This struggle is evident when examining the growth metrics that truly signal expansion: employer and health-plan relationships, enterprise contract depth, and covered-lives volume. Pear’s inability to consistently secure these, despite its FDA bona fides, proved fatal. The company’s public filings with the SEC prior to its bankruptcy highlighted these commercialization hurdles, signaling a mismatch between the perceived value of their clearances and the actual revenue generation. SEC filings for Pear Therapeutics

This situation stands in contrast to companies that have focused on clear reimbursement pathways from the outset, or those operating in areas with established billing codes. The market’s reaction, as reflected in the dramatic drop in valuation (CW6-DP-12: Pear 1.6B peak to 6.05M asset sale), provides a stark lesson for the entire AI health ecosystem.

Root Causes: The Reimbursement Chasm and Market Readiness

The primary root cause of Pear Therapeutics’ downfall was not a lack of innovation or clinical evidence, but a fundamental misjudgment of the market’s readiness and the complexity of healthcare reimbursement. The FDA CDRH (Center for Devices and Radiological Health) successfully evaluated Pear’s products for safety and efficacy, granting clearances via the De Novo pathway for novel solutions and potentially 510(k) for others, where applicable. However, FDA clearance, whether De Novo or 510(k), does not automatically translate into a CPT code or a coverage decision from CMS or private health plans.

The healthcare system, particularly in the US, is notoriously slow to adapt to new payment models. Digital therapeutics, as a new category, lacked established Category I CPT codes, often relying on less reliable Category III codes or direct contracting. This created significant friction for providers and health systems attempting to bill for Pear’s products, leading to inconsistent adoption. CMS, as the largest payer, sets critical precedents, and their reluctance or slow pace in establishing clear reimbursement policies for DTx left a significant gap. While Medicare’s Digital Mental Health Treatment (DMHT) codes became operational in 2025, allowing for reimbursement of specific regulated digital therapeutics under clinical supervision, reimbursement limitations and regulatory challenges continue to restrict widespread adoption of digital therapeutics solutions. Rock Health, in its analyses of digital health funding and market trends, has consistently highlighted reimbursement as a key barrier for innovative health technologies, a challenge Pear evidently could not overcome at scale. Rock Health reports on digital health reimbursement

While companies like Omada Health and Big Health have found success through direct-to-employer and health-plan contracts, often bypassing traditional fee-for-service reimbursement, Pear’s model struggled to achieve the necessary enterprise contract depth and covered-lives volume to sustain its operations. Akili Interactive, another FDA-cleared DTx company, faces similar reimbursement headwinds, demonstrating that Pear’s challenge was not isolated but indicative of a systemic issue for this class of products. Click Therapeutics, while also in the DTx space, has pursued different partnership strategies, highlighting the varied approaches companies take to navigate this complex landscape.

Expert Perspectives on the Commercialization Gap

Prominent voices in healthcare and technology have long warned about the commercialization gap in digital health. Vinod Khosla, a seasoned venture capitalist, has often emphasized that technological breakthroughs alone are insufficient; the path to market and sustainable business models are equally, if not more, critical. His focus on impact and scalability implicitly includes the ability to integrate into existing healthcare economics. The Pear Therapeutics case serves as a vivid illustration of this principle.

Similarly, Dr. Eric Topol, a leading cardiologist and digital health thought leader, has consistently advocated for the integration of validated digital tools into clinical practice. However, he also frequently points to the systemic hurdles, including reimbursement, that impede widespread adoption, even for clinically proven innovations. The failure of Pear, despite its FDA clearances, underscores the chasm between regulatory validation and practical implementation within a complex payment environment. As Dr. Topol might argue, the science was there, but the operational framework for widespread access and payment was not. Eric Topol’s writings on digital health adoption barriers

The consensus among these experts suggests that while FDA approval signifies a product’s safety and efficacy, it is merely the first step. The subsequent, and often more arduous, journey involves securing robust reimbursement and demonstrating value to payers in a language they understand: cost savings, improved outcomes, and reduced total cost of care, all within established billing mechanisms.

Implications for Investors, Buyers, and Health Plans

The Pear Therapeutics saga offers critical lessons for investors, health plans, and enterprise buyers in the AI health sector. For investors, the takeaway is clear: FDA clearance is a necessary but insufficient condition for success. Diligence must extend far beyond regulatory status to a deep understanding of the proposed reimbursement model, the depth of existing health-plan relationships, and the potential for scalable enterprise contracts. Companies demonstrating strong employer and health-plan expansion signals, coupled with a clear path to covered-lives volume, are inherently de-risked compared to those solely relying on regulatory milestones. The “data moat” built through proprietary datasets and real-world evidence, crucial for AI model performance and payer negotiation, should be a key evaluation criterion.

For health plans and enterprise buyers, the cautionary tale highlights the importance of demanding clear evidence of both clinical efficacy and economic value. When evaluating AI health solutions, look beyond the FDA badge to scrutinize the company’s ability to integrate seamlessly into existing care pathways and, crucially, its capacity to secure sustainable reimbursement. The growth of validated AI health companies will increasingly hinge on their ability to navigate this complex landscape, proving that regulatory scrutiny, while increasing, also pushes companies toward more robust commercialization strategies from the outset. The ultimate growth-metrics analysis must therefore encompass not just clinical validation, but also the arduous journey through the reimbursement labyrinth.